| First Author | Nesfield SR | Year | 2005 |
| Journal | Int J Toxicol | Volume | 24 |
| Issue | 5 | Pages | 341-8 |
| PubMed ID | 16257853 | Mgi Jnum | J:104336 |
| Mgi Id | MGI:3611679 | Doi | 10.1080/10915810500210401 |
| Citation | Nesfield SR, et al. (2005) Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse. Int J Toxicol 24(5):341-8 |
| abstractText | This study was conducted in support of the International Life Sciences Institute (ILSI) alternative carcinogenicity models initiative to evaluate the carcinogenic potential of clofibrate, a nongenotoxic peroxisome proliferator-activated receptor (PPAR) alpha agonist, following oral administration to neonatal mice. Male and female neonatal CD-1 mice were dosed with clofibrate at doses of 100, 250, and 500 mg/kg or with the positive control, diethylnitrosamine (DEN), at 2 mg/kg by oral gavage on days 9 and 16 post birth and observed for approximately 1 year for the development of tumors. Plasma levels of clofibric acid after the second administration increased with dose, but were not dose proportional. Clofibrate administered by gavage on litter days 9 and 16 to neonatal mice at doses of 100, 250, or 500 mg/kg did not produce a carcinogenic effect. The positive control DEN did produce tumors in the liver and lung (single and multiple adenomas and carcinomas) and harderian gland (adenoma) of both sexes. Non-neoplastic lesions related to DEN treatment were confined to myocardial degeneration/fibrosis and testicular interstitial hyperplasia in males, and to glomerulonephrosis and gastritis in both sexes. |
